We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across various health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further research is needed to better understand the relationship between SF levels and specific health-related quality of life domains.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Lefèvre C, Bondu S, Le Goff S, Kosmider O, Fontenay M. Dyserythropoiesis of myelodysplastic syndromes. Curr Opin Hematol. 2017;24(3):191–7.
Lyle L, Hirose A. Iron Overload in myelodysplastic syndromes: pathophysiology, consequences, diagnosis, and treatment. J Adv Pract Oncol. 2018;9(4):392–405.
Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, et al. Iron toxicity - Its effect on the bone marrow. Blood Rev. 2018;32(6):473–9.
Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107(1):55–63.
Wood JC. Guidelines for quantifying iron overload. Hematol Am Soc Hematol Edu. 2014;2014(1):210–5.
Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–64.
Caocci G, La Nasa G, Efficace F. Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol. 2009;2(1):69–80.
Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Richards PD, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: registry analysis at 5 years. Leuk Res. 2017;56:88–95.
Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, et al. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. BMJ Support Palliat Care. 2016;6(1):80–8.
Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, et al. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia. 2020;2:13–7. https://doi.org/10.1038/s41375-41020-40746-41378.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(1):89–96.
Fozza C, La Nasa G, Caocci G. The Yin and Yang of myelodysplastic syndromes and autoimmunity: the paradox of autoimmune disorders responding to therapies specific for MDS. Crit Rev Oncol Hematol. 2019;142:51–7.
Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32(6):1380–92.
Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2015;168(3):361–70.
Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2020;105(3):640–51.
The authors gratefully acknowledge all patients who participated in the GIMEMA-PROMYS Study for dedicating their time in completing quality of life questionnaires and having contributed in advancing knowledge in this research area. We also acknowledge the important contribution over the years to the coordination of the Data Management activities of Dr. Francesco Sparano.
Conflict of interests
Massimo Breccia: Honoraria by Novartis, Pfizer, Incyte, Celgene, outside the submitted work. Fabio Efficace: personal fees from Bristol-Myers Squibb, Amgen, Orsenix, Incyte and Takeda; grants from Amgen, outside the submitted work. Mario Luppi: Advisory Boards: Novartis, Gilead Sci, Abbvie, Celgene, MSD, Sanofi, Daiichi-Sankyo; Travel Grant Gilead sci, outside the submitted work. Giuseppe A. Palumbo: Honoraria from Jannsen, Novartis, Celgene, Amgen, outside the submitted work. Marco Vignetti: personal fees from Jazz Healthcare Italy SRL, Amgen, Millennium Pharmaceuticals Inc., Celgene, Janssen, Novartis and Incyte, outside the submitted work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Caocci, G., Vignetti, M., Patriarca, A. et al. High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. Int J Hematol (2020). https://doi.org/10.1007/s12185-020-02920-y
- Serum ferritin
- Myelodysplastic syndromes
- Functional status
- Quality of life